BDX — Becton, Dickinson and Company

Is BDX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Oversold As of October 3, 2026

Becton, Dickinson and Company (BDX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $176.80. The rating moved from Neutral to Oversold on September 30, 2026.

See all oversold Healthcare stocks →

AI analysis

Becton, Dickinson and Company (BDX) is a large, diversified medtech company with resilient consumables revenue and strong exposure to injectable delivery and life‑sciences markets. Defensive sector flows and growing demand for injectable therapies (GLP‑1s, biologics, combination regimens) support steady top‑line traction. The firm’s cash flow, scale and manufacturing footprint underpin the ability to invest in capacity and M&A, though payer/Medicare pricing dynamics, supply‑chain pressures and regulatory risks present potential headwinds. Near term, expect limited directional market moves absent company-specific catalysts; over a multi‑quarter horizon, upside is driven by execution on sterile manufacturing, consumables penetration and successful integration of strategic investments.

Key factors

  • Becton, Dickinson and Company (BDX) benefits from defensive demand for medical devices and supplies, which tends to hold up in risk-off environments.
  • Strong exposure to injectable drug delivery and single-use devices positions BDX to capture incremental demand from the expanding GLP-1/amylin and biologics markets.
  • Large installed base, diversified end markets (hospitals, life sciences, ambulatory care) and recurring consumables revenue support stable cash flow and margin resilience.
  • Solid balance sheet and free-cash-flow generation enable ongoing R&D, manufacturing investments and selective M&A to sustain long-term growth.
  • Recent market flows into defensive healthcare names amid geopolitical uncertainty create near-term support for shares.
  • Ongoing earnings season commentary and rate-path uncertainty create a backdrop where clear execution and guidance transparency can drive re-rating.

Risks

  • Downward pricing pressure or procurement delays from large institutional buyers and payers, amplified by Medicare negotiation/policy changes, could compress device ASPs or delay purchases.
  • Supply-chain disruptions or input-cost inflation could erode margins or delay shipments, especially for complex device assemblies and sterile manufacturing.
  • Intensifying competition from large medtech peers and new entrants (including contract manufacturers and device+software hybrids) could pressure share and pricing over time.
  • Regulatory or product-approval setbacks, recalls or litigation in high-volume product lines would hit revenue and margins disproportionately.
  • Macroeconomic weakness or hospital capital spending cutbacks could reduce elective procedure volumes and consumables usage growth.
  • Execution risk on manufacturing scale-up for injectable-related products and any M&A integration missteps could limit near-term upside.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for BDX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.